Thermo Fisher Completes Finnzymes Acquisition | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has completed its acquisition of Finnzymes for an undisclosed sum.

Espoo, Finland-based Finnzymes makes reagents, consumables, kits, and instruments for molecular biology applications. Its proprietary DNA polymerases, called Phire and Phusion, and high-speed miniaturized thermal cyclers will expand Thermo Fisher's portfolio of reagents and other consumables for the molecular biology research and diagnostics markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.